<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">179</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2018-5-4-104-109</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Immunohistochemical evaluation of vimentin aberrant expression in lung carcinoid tumors</article-title><trans-title-group xml:lang="ru"><trans-title>Иммуногистохимический анализ аберрантной экспрессии виментина в карциноидных опухолях легкого</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4550-2069</contrib-id><name-alternatives><name xml:lang="en"><surname>Delektorskaya</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Делекторская</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>Вера Владимировна Делекторская.</p><p>115478 Москва, Каширское шоссе, 24</p></bio><email>delektorskaya@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chemeris</surname><given-names>G. Yu.</given-names></name><name xml:lang="ru"><surname>Чемерис</surname><given-names>Г. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3330-337X</contrib-id><name-alternatives><name xml:lang="en"><surname>Smirnova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Смирнова</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2018</year></pub-date><volume>5</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>104</fpage><lpage>109</lpage><history><date date-type="received" iso-8601-date="2019-01-04"><day>04</day><month>01</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-01-04"><day>04</day><month>01</month><year>2019</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Delektorskaya V.V., Chemeris G.Y., Smirnova E.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, Делекторская В.В., Чемерис Г.Ю., Смирнова Е.А.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Delektorskaya V.V., Chemeris G.Y., Smirnova E.A.</copyright-holder><copyright-holder xml:lang="ru">Делекторская В.В., Чемерис Г.Ю., Смирнова Е.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/179">https://umo.abvpress.ru/jour/article/view/179</self-uri><abstract xml:lang="en"><p><bold>Objective:</bold> to the study of the vimentin aberrant expression in the carcinoid tumors of lung, which is a rare group of epithelial neuroendocrine neoplasms with common morphological characteristics and highly variable clinical course.</p><p><bold>Materials and methods.</bold> Vimentin expression was studied using immunohistochemical analysis in neoplasms of 34 patients with lung carcinoid tumors, which included 17 cases in the categories of typical and atypical carcinoids.</p><p><bold>Results</bold>. Overall positive cytoplasmic immunoreactivity was observed in 9 (26.5 %) of the 34 studied tumors. Staining for vimentin was positive in 2 (11.8 %) of typical carcinoid and in 7 (41.2 %) of atypical carcinoid specimens. Expression of vimentin was more often observed  in the atypical carcinoids category and was significantly associated with increased grade (p = 0.05), and cell proliferation taking into account the Ki-67 index (p = 0.008).</p><p><bold>Conclusion.</bold> These results suggest that expression of vimentin as an epithelial-mesenchymal transition-related marker plays an important role in the progression of carcinoid tumors. It may prove useful for diagnostic purposes, and also be used as a potential criterion for prognosis assessment of this type of tumors.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>lung carcinoid tumor</kwd><kwd>vimentin</kwd><kwd>immunohistochemistry</kwd><kwd>diagnosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>карциноидная опухоль легкого</kwd><kwd>виментин</kwd><kwd>иммуногистохимия</kwd><kwd>диагностика</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Travis W.D., Brambilla E., Burke A.P. et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. IARC Press: Lyon, 2015.</mixed-citation><mixed-citation xml:lang="ru">Travis W.D., Brambilla E., Burke A.P. et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. IARC Press: Lyon, 2015.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Rindi G., Klersy C., Inzani F. et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 2013;21(1):1–16. DOI: 10.1530/ERC-13-0246. PMID: 24344249.</mixed-citation></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Delektorskaya VV Neuroendocrine tumors of the lung: the current classification and pathology diagnosis algorithm. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2017;4(2):46—58. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Делекторская В.В. Нейроэндокринные опухоли легкого: современная классификация и алгоритм морфологической диагностики. Успехи молекулярной онкологии 2.017;4(2):46—58. DOI: 10.17650/2313-805X-2017-4-2-46-58.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><mixed-citation>Davis F.M., Stewart T.A., Thompson E.W., Monteith G.R. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci 2014;35(9):479—88. DOI: 10.1016/j.tips.2014.06.006. PMID: 25042456.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Mittal V. Epithelial mesenchymal transition in aggressive lung cancers. Adv Exp Med Biol 2016;890:37-56. DOI: 10.1007/978-3-319-24932-2_3. PMID: 26703798.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Zhang Y., Weinberg R.A. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med 2018;12(4):361 —73 DOI: 10.1007/s11684-018-0656-6. PMID: 30043221.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Prieto-Garcia E., Diaz-Garcia C.V., Gar-cia-Ruiz I., Agullo-Ortuno M.T. Epitheli-al-to-mesenchymal transition in tumor progression. Med Oncol 2017;34(7):122.</mixed-citation></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Vasilenko I.V., Kondratyuk R.B., Kudryashov A.G. et al. The features of epithelial-mesenchymal transition in cancers of various localizations and histological structure. Klinicheskaya onkologiya = Clinical Oncology 2012;5(1):163—7. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Василенко И.В., Кондратюк Р.Б., Кудряшов А.Г. и др. Особенности эпителиально-мезенхимальной трансформации в раках различной локализации и гистологического строения. Клиническая онкология 2012;5(1):163—7.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><mixed-citation>Qureshi R., Arora H., Rizvi M.A. EMT in cervical cancer: its role in tumour progression and response to therapy. Cancer Lett 2015; 356(2 Pt B):321—31. DOI: 10.1016/j.canlet.2014.09.021. PMID: 25281477.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kidd M.E., Shumaker D.K., Ridge K.M. The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol 2014;50(1):1— 6. DOI: 10.1165/rcmb.2013-0314TR. PMID: 23980547.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Du L., Li J., Lei L. et al. High vimentin expression predicts a poor prognosis and progression in colorectal cancer: a study with meta-analysis and TCGA database. Biomed Res Int 2018;2018:6387810. DOI: 10.1155/2018/6387810. PMID: 29955607.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Singla M., Kumar A., Bal A. et al. Epithelial to mesenchymal transition induces stem cell like phenotype in renal cell carcinoma cells. Cancer Cell Int 2018;18:57. DOI: 10.1186/s12935-018-0555-6. PMID: 29681769.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Satelli A., Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 2011;68(18):3033—46. DOI: 10.1007/s00018-011-0735-1. PMID: 21637948.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Fendrich V., Maschuw K., Waldmann J. et al. Epithelial-mesenchymal transition is a critical step in tumorgenesis of pancreatic neuroendocrine tumors. Cancers (Basel) 2012;4(1):281—94. DOI: 10.3390/can-cers4010281. PMID: 24213240.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Yonemori K., Kurahara H., Maemura K. et al. Impact of Snail and E-cadherin expression in pancreatic neuroendocrine tumors. Oncol Lett 2017;14(2):1697—702. DOI: 10.3892/ol.2017.6306. PMID: 28789397.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Galvan J.A., Astudillo A., Vallina A. et al. Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors. BMC Cancer 2014;14:855. DOI: 10.1186/1471-2407-14-855. PMID: 25413006.</mixed-citation></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Ponomarenko E.A., Bogush T.A., Mamichev I.A. et al. Expression of vimentin — molecular marker of cell metastatic potential in tissues of nonsmall cell lung cancer and stomach cancer. Zlokachestvennye opukholi = Malignant Tumors 2017;7(3):89. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Пономаренко Е.А., Богуш Т.А., Мами-чев И.А. и др. Экспрессия виментина — молекулярного маркера метастатического потенциала клеток, в ткани немелкоклеточного рака легкого и рака желудка. Злокачественные опухоли 2017;7(3):89.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
